Online inquiry

IVTScrip™ mRNA-Anti-KDR, Angiocept(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2992MR)

This product GTTS-WQ2992MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets KDR gene. The antibody can be applied in Colorectal Cancer (CRC) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_002253.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3791
UniProt ID P35968
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-KDR, Angiocept(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ2992MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15189MR IVTScrip™ mRNA-Anti-TNF, TA-650(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA TA-650
GTTS-WQ1513MR IVTScrip™ mRNA-Anti-INHBA, ACE-011(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ACE-011
GTTS-WQ6161MR IVTScrip™ mRNA-Anti-IGF1R, CP-751871(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CP-751871
GTTS-WQ1957MR IVTScrip™ mRNA-Anti-SLITRK6, AGS-15E(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AGS-15E
GTTS-WQ7295MR IVTScrip™ mRNA-Anti-CSF1R, FPA-008(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA FPA-008
GTTS-WQ6364MR IVTScrip™ mRNA-Anti-MSTN, CSL-362-AML(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CSL-362-AML
GTTS-WQ14894MR IVTScrip™ mRNA-Anti-stx1B, Shigamabs®(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ7480MR IVTScrip™ mRNA-Anti-TGFB, GC-1008(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GC-1008
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW